Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and diagnostics, is pleased to announce that, further to its announcement on 28 February 2024, the Company has successfully
Avacta Group PLC (AIM:AVCT) Appointment of Christina Coughlin
Appointment of Christina Coughlin, M.D., Ph.D. as Head of Research and Development
Avacta Group PLC (AIM:AVCT) Appointment of Chief Business Officer
Appointment signals commercial emphasis for Avacta to leverage clinical progress
Avacta Group PLC – ALS-6000-101 Phase 1a Study Data
The data confirm the pre|CISIONTM platform’s ability to transform the safety profile of doxorubicin through tumour targeting Cohort 7, the final cohort in the three-weekly dose escalation safety study of AVA6000,
Avacta Group PLC (AIM:AVCT) Shareholder update to review AVA6000 Phase 1a data
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will hold an online shareholder event via the Investor Meet Company (“IMC”) platform
Avacta Group PLC (AIM:AVCT) Successful Completion of Sixth Dose Escalation
Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update
Avacta Group PLC (AIM:AVCT) Notice of Results
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will announce its unaudited interim results for the six months ended 30 June
Avacta Group PLC (AIM:AVCT) Completion of Fifth Dose Escalation in AVA6000
Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study
Avacta Group PLC (AIM:AVCT) Statement regarding market speculation
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, notes the recent market speculation regarding possible fundraising.
Avacta Group PLC (AIM:AVCT) AGM and Shareholder Event Detailed Agenda
Avacta Annual General Meeting and Shareholder Event Detailed Agenda
Avacta Group PLC – Second Milestone in AffyXell Joint Venture
Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake
Avacta Group PLC – Posting of Annual Report and Notice of AGM
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that its Annual Report and Accounts for the year ended 31 December